These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6223322)

  • 1. Dopamine autoreceptor stimulation: clinical significance.
    Meltzer HY
    Pharmacol Biochem Behav; 1982; 17 Suppl 1():1-10. PubMed ID: 6223322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies.
    Meltzer HY
    Schizophr Bull; 1980; 6(3):456-75. PubMed ID: 6105707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine agonists and antagonists in Tourette's disease.
    Feinberg M; Carroll BJ
    Arch Gen Psychiatry; 1979 Aug; 36(9):979-85. PubMed ID: 380492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
    Jeziorski M; White FJ
    Synapse; 1989; 4(4):267-80. PubMed ID: 2603146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of mesocortical dopamine neurons.
    Bannon MJ; Roth RH
    Pharmacol Rev; 1983 Mar; 35(1):53-68. PubMed ID: 6138783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum.
    Hársing LG; Vizi ES
    Pol J Pharmacol Pharm; 1985; 37(3):383-96. PubMed ID: 2866504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique response to antipsychotic drugs is due to absence of terminal autoreceptors in mesocortical dopamine neurones.
    Bannon MJ; Reinhard JF; Bunney EB; Roth RH
    Nature; 1982 Apr; 296(5856):444-6. PubMed ID: 7063040
    [No Abstract]   [Full Text] [Related]  

  • 10. Neurophysiological evidence that D-1 dopamine receptor blockade attenuates postsynaptic but not autoreceptor-mediated effects of dopamine agonists.
    Carlson JH; Bergstrom DA; Walters JR
    Eur J Pharmacol; 1986 Apr; 123(2):237-51. PubMed ID: 2940101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midification of tardive dyskinesia and spasmodic torticollis by apomorphine. Possible role of dopamine autoreceptors.
    Tolosa ES
    Arch Neurol; 1978 Jul; 35(7):459-62. PubMed ID: 666598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Functional role and pharmacological regulation of the dopaminergic system of the brain].
    Raevskiĭ KS
    Vestn Ross Akad Med Nauk; 1998; (8):19-24. PubMed ID: 9771125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The supersensitivity of dopaminergic neurons to apomorphine in rats following chronic haloperidol.
    Vogelsang GD; Piercey MF
    Eur J Pharmacol; 1985 Apr; 110(2):267-9. PubMed ID: 3987817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in sensitivity of release modulating dopamine autoreceptors after chronic treatment with haloperidol.
    Nowak JZ; Arbilla S; Galzin AM; Langer SZ
    J Pharmacol Exp Ther; 1983 Aug; 226(2):558-64. PubMed ID: 6875865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative potency of dopamine agonists on autoreceptor function in various brain regions of the rat.
    Westfall TC; Naes L; Paul C
    J Pharmacol Exp Ther; 1983 Jan; 224(1):199-205. PubMed ID: 6848743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ontogeny of nigrostriatal dopamine neuron autoreceptors: iontophoretic studies.
    Wang L; Pitts DK
    J Pharmacol Exp Ther; 1995 Jan; 272(1):164-76. PubMed ID: 7815330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.